Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.

CONCLUSION: The present synthesis found that gabexate mesilate could be an option of prophylactic treatment of pancreatitis for patients undergoing ERCP, and reveals that it is favorable to administer it starting 30 min before the ERCP. This evidence may improve the clinical prevention of PEP. PMID: 33183879 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33183879?dopt=Abstract

Source: J Formos Med Assoc - November 9, 2020 Category: General Medicine Authors: Chiu YJ, Chen SC, Kang YN, Hou SK, Chao CC, Chang CC Tags: J Formos Med Assoc Source Type: research